The Bert M. Glaser, MD Award for Innovative Research in Retina
This award is given to an early-career investigator in recognition of the discovery of a drug or technique, or the understanding of a mechanism of disease, that is novel and has profoundly changed our understanding and/or treatment of a retinal disease or condition. The discovery must have taken place within five years of the date of application.
This award honors the life of Bert M. Glaser, MD, a retinal surgeon, researcher, innovator and teacher for over 30 years. The award was established by his family to honor his legacy as an innovator and as a retina specialist.
The $10,000 award is supported by the Glaser family through the ARVO Foundation. The first award was issued in 2019.
Nominations are closed
- Must be a basic scientist or clinician-scientist in retina
- Must be within five years of completion of a post-doctoral fellowship or clinical fellowship
- Must be an ARVO member
- May be a resident or citizen of any country
- May be affiliated with a university, hospital, private practice or company
Letters of Support
Two letters are required to support this nomination: one from the Nominator and one from a secondary Supporter.
The Nominator is responsible for obtaining and uploading his/her own letter of nomination and the letter of the secondary Supporter. Nominators and Supporters may only support one nomination; the Nominator and the Supporter may not be from the same institution. Foundation and ARVO Officers, Board members and Awards Committee members are not eligible to nominate or be nominated for an award during their terms, or to offer seconding letters of support.
The letters should address the following:
- How the nominee has contributed to the discovery of a drug or technique, or the understanding of a mechanism of disease, that is novel and has profoundly changed our understanding and/or treatment of a retinal disease or condition
- The timeframe in which the discovery or understanding was achieved (must be by 9/1/2018 or later)
- Mention of any publications that reference this discovery or understanding
The award will be disbursed to the winner’s employer for the sole purpose of furthering the winner’s research. The applicant’s employer must be willing to receive and disburse the award monies under the guidelines of ARVO. It is the responsibility of the applicant to ensure his/her employer can and will accept the award monies for the sole purpose set out in this award, as specified in the criteria, including that the employer agrees not to apply or withhold administrative fees or indirect costs.
Applications open on July 1
Applications close on Sept. 1
Recipient notified in December
2023 recipient: Miguel Flores-Bellver, PhD
Dr. Flores-Bellver received a Pharm.D. degree from the University of Valencia in Spain in 2010, followed by a Master’s degree in Biomedical Research in 2012. In 2015, he earned his International PhD in cell and molecular biology from the Catholic University of Valencia. After earning his PhD, Flores-Bellver joined the Wilmer Eye Institute at Johns Hopkins University as a postdoctoral fellow in Eye Development. He stayed in this position until 2018 when he moved to the University of Colorado Denver as a postdoctoral fellow. In 2020, Flores-Bellver was promoted to a faculty position as a research instructor in the Department of Ophthalmology and a principal investigator at the CellSight-Ocular Stem Cell and Regeneration Program. He is currently the director of The Human Stem Cells Exosome Lab (ExoSight).